Background: Reliable biomarkers of sunitinib response in gastrointestinal stromal tumor (GIST) are lacking.
introduction Current management of gastrointestinal stromal tumor (GIST) centers on inhibition of the related receptor tyrosine kinases (RTKs) KIT and platelet-derived growth factor receptor (PDGFR)-α due to the presence of activating mutations in KIT or PDGFRA in most tumors [1] . Metastatic GIST treated with the tyrosine kinase inhibitor (TKI) imatinib in the first-line treatment setting leads to disease control (objective response or stable disease) in over 80% of patients [2] . In the second-line treatment setting, sunitinib malate (SUTENT®; Pfizer Inc., New York, NY, USA) controls disease in over 60% of patients [3] . Although primary tumor genotype remains a strong predictor of response to first-line therapy [4] , reliable biomarkers for predicting response to subsequent lines of therapy are lacking.
Activation of vascular endothelial growth factor receptor (VEGFR)-2 by VEGF is associated with hypotensive and vasodilatory effects in vascular endothelial cells [5, 6] . Therefore, inhibition of the VEGF-VEGFR-2 signaling axis would be expected to lead to increases in peripheral vascular resistance. Possible mechanisms of VEGF inhibitor-induced hypertension (HTN) include interruption of endothelial cell survival signaling, leading to apoptosis and capillary rarefaction [7] , inhibition of endothelial production of nitric oxide, leading to constriction of vascular smooth muscle cells [5, 6] , and activation of the endothelin-1 pathway [8] . HTN is a demonstrated class effect of agents targeting the VEGF signaling pathway, including sunitinib, bevacizumab, sorafenib, cediranib, and axitinib [9] [10] [11] . As such, HTN has been proposed as a biomarker of clinical outcome for these agents [12] [13] [14] .
The oral multitargeted TKI sunitinib has activity against a range of RTKs, including KIT, PDGFR-α and -β, and VEGFR-1, -2, and -3 [15] [16] [17] [18] . Sunitinib is approved multinationally for the treatment of imatinib-resistant/-intolerant GIST based on results showing a significant increase in time to tumor progression (TTP) compared with placebo in patients with metastatic GIST previously treated with imatinib [3] . In addition, sunitinib is approved for use in advanced renal cell carcinoma (RCC) and pancreatic neuroendocrine tumors [18] . In a study of patients with advanced RCC treated with sunitinib, on-treatment HTN significantly predicted improved objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) [19] . Preliminary results in GIST have demonstrated a significant association between sunitinib therapy and increased incidence of HTN. Furthermore, median OS was more than twofold higher in sunitinib-treated patients with HTN compared with those without, suggesting that HTN may be predictive of prolonged OS in this patient group [20] .
Based on these observations, a retrospective exploratory analysis was conducted to investigate whether sunitinibinduced HTN in patients with GIST correlated with antitumor efficacy and development of HTN-associated adverse events (AEs). The goal of this analysis was to determine whether sunitinib-associated HTN could be a biomarker of efficacy without unacceptable toxic effect in this patient population.
patients and methods patients
This analysis included data from three clinical trials of sunitinib in advanced GIST [3, 21, 22] . Common eligibility criteria were histologically confirmed, imatinib-resistant/-intolerant GIST, adequate hepatic and hematologic function, absence of symptomatic congestive heart failure, myocardial infarction, or coronary artery bypass graft in the previous 6 or 12 months depending on the study, severe/unstable angina either ongoing or in the previous 12 months, or ongoing unstable arrhythmia. Additional eligibility criteria for patients included in efficacy analyses were age ≥18 years, Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1, adequate renal function, and normal left ventricular ejection fraction and corrected QT interval.
study design
Efficacy analyses were conducted on pooled data from two prospective clinical trials of sunitinib in imatinib-resistant/-intolerant GIST [3, 21] , comprising 319 sunitinib-treated patients for whom post-baseline blood pressure (BP) data were available (Table 1) . One study was a phase I doseescalation/early phase II trial in which 97 patients received open-label sunitinib [21] . Sunitinib 50 mg/day administered in cycles of 4 consecutive weeks on treatment followed by 2 weeks off treatment (schedule 4/2) was the dosing schedule selected for the phase II portion of the study. The other trial was a randomized, double-blind, placebo-controlled phase III study utilizing a crossover design to evaluate the efficacy and safety of sunitinib 50 mg/day on schedule 4/2 [3, 23] ; 222 patients in the sunitinib arm of this study received double-blind sunitinib, followed in some cases by open-label sunitinib after unblinding, and were evaluated for efficacy in the present analysis. The current safety analysis included pooled data from 1565 patients from three trials: 97 patients from the phase I/II study [21] ; 344 patients from the phase III study who received double-blind or openlabel sunitinib, including those who received sunitinib following crossover from placebo [23] ; and 1124 patients from a treatment-use study ( BP was measured on days 1 and 28 of dosing in each treatment cycle. Cut-offs for HTN were chosen prospectively based on the guidelines described in the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) [24] . HTN was defined as maximum (efficacy analyses) or mean (safety analyses) systolic BP (SBP) ≥ 140 mmHg and/or diastolic BP (DBP) ≥ 90 mmHg at any time after day 1 of treatment. A combined definition of HTN (elevated SBP and/or DBP) was used for consistency with JNC 7 criteria and National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 3.0 [24, 25] . This approach also agrees with similar prior published analyses with targeted cancer therapies [12, 14] .
Efficacy measures analyzed were ORR, TTP, PFS, and OS. HTNassociated AEs evaluated included prespecified cardiovascular, cerebrovascular, ocular, and renal AEs as described in JNC 7. AEs were graded using NCI CTCAE version 3. Safety analyses used mean SBP and DBP measurements calculated based on an average of 17 post-baseline measurements over a range of 1-44 treatment cycles.
statistical methods
Time-to-event endpoints were assessed using Kaplan-Meier methods and compared between patients with and without HTN using the log-rank test. The influence of baseline factors on time-to-event endpoints was assessed using a Cox proportional hazards model, with individual factors subjected to univariate and multivariate analyses using a stepwise algorithm. Factors in univariate analysis with P < 0.2 were entered into a multivariate model, in which additional elimination was applied to identify significant variables (28) 63 (26) 25 (21) 375 (33) A Cox proportional hazards model with HTN onset as a timedependent covariate was used to estimate hazard ratios for time-to-event endpoints. Landmark analyses were conducted using Kaplan-Meier methods to evaluate associations between early HTN and time-to-event endpoints at the end of treatment cycles 1 or 2. Patients who progressed (TTP and PFS only), died (PFS and OS only), or discontinued (TTP, PFS, and OS) before each landmark were excluded from analysis.
All P-values were two-sided, confidence intervals (CIs) were set at the 95% level, and no adjustment was made for multiple comparisons. Correlations between sunitinib dosing and maximum BP were made using Pearson's correlation tests. Comparisons of selected HTN-associated complications between groups were made using the Pearson's χ 2 -test and
Fisher's exact test.
results patient characteristics
Demographics and baseline characteristics of patients included in this analysis are presented in Table 1 . Median ages of patients ranged from 55 to 59 years. Most patients had an ECOG PS of 0 or 1, and ∼30% were reported to have HTN at or before study entry.
HTN status
Median baseline SBP over DBP among patients with and without HTN during sunitinib treatment was 130 over 76 mmHg and 112 over 72 mmHg, respectively. Among the 319 patients included in the efficacy analyses, 247 (77%) experienced at least one episode of on-treatment HTN (noting that the absolute BP-based definition used in the present analysis yielded a higher incidence of HTN than that reported previously using CTCAE [18] ). Treatment-associated HTN occurred soon after initiation of sunitinib therapy, with a median time to HTN onset of 4 weeks (range <1-70 weeks). Percentages of patients with HTN by the end of treatment cycles 1 and 2 were 58% and 66%, respectively. Sunitinib RDI showed little correlation with maximum SBP (r = 0.069) or maximum DBP (r = 0.056).
correlation between HTN and antitumor efficacy HTN during sunitinib treatment was associated with improved clinical outcomes ( Table 2) . ORRs were 16% and 3% in patients with and without HTN, respectively (P = 0.004). In patients with and without HTN, median TTP was 34 versus 16 weeks (P < 0.0001) as was median PFS, and median OS was 87 versus 53 weeks (P = 0.0003; Figure 1) . A Cox proportional hazards model with HTN onset as a time-dependent covariate was used to address the potential bias resulting from greater drug exposure in patients who survived longer, and therefore, had an increased likelihood of developing treatment-induced HTN. HTN significantly predicted prolonged OS, but not TTP or PFS in this analysis (supplemental Table S1 , available at Annals of Oncology online).
Landmark analyses were undertaken to address the potential bias from misclassification of patients who may not have remained sufficiently long on study for HTN to develop (Table 3) . At the end of treatment cycle 1 at 6 weeks, median TTP was significantly greater among patients with HTN versus those without (34 versus 24 weeks, respectively; P = 0.012), as was median PFS (33 versus 23 weeks; P = 0.010). At 6 weeks, there was a trend towards significantly greater OS in patients with HTN versus those without (79 versus 67 weeks; P = 0.061). At the end of treatment cycle 2 at 12 weeks, median TTP was significantly greater among patients with HTN versus those without (34 versus 18 weeks; P = 0.0002), as was median PFS (34 versus 18 weeks; P = 0.0005) and OS (79 versus 58 weeks; P = 0.042).
Clinical outcomes did not appear to be compromised in patients who received antihypertensive medications during sunitinib treatment. Median TTP, PFS, and OS among patients with HTN who received antihypertensives (n = 123) were 30 weeks (95% CI 23-34), 28 weeks (95% CI 22-34), and 82 weeks (95% CI 71-93), respectively. (Table 4) .
correlations between HTN and HTN-associated AEs
To determine the clinical significance of HTN during sunitinib treatment, rates of any grade and grade ≥3 cardiovascular, cerebrovascular, ocular, and renal AEs of any cause were evaluated in sunitinib-treated patients with and without HTN, defined as mean SBP ≥ 140 mmHg and/or mean DBP ≥ 90 mmHg (Table 5 ). Safety analyses were based on mean and not maximum BP measurements because elevations in BP over time were judged to have a greater potential impact on end-organ function than isolated maximum BP elevations. Overall incidences of cardiovascular, cerebrovascular, and ocular AEs were low and similar between patients with and without HTN. Patients with HTN had higher incidences of cardiovascular AEs of any grade (7% versus 4%; P = 0.044) and grade ≥3 severity (5% versus 2%; P = 0.004) compared with patients without HTN. Similarly, patients with HTN had a higher incidence of cardiac failure (any grade: 2% versus <1%, P = 0.013; grade ≥3: 1% versus <1%, P = 0.005) and congestive cardiac failure (any grade: 1% versus <1%, P = 0.034; grade ≥3: 1% versus <1%, P = 0.035) than those without HTN.
discussion
This retrospective analysis found that sunitinib-associated HTN correlated with improved clinical outcomes in patients with advanced GIST, with significant benefits in ORR, TTP, PFS, and OS demonstrated for patients with HTN compared with those without. Time-dependent covariate analysis confirmed these findings for OS, suggesting that this effect was not simply an epiphenomenon resulting from the selection of patients who lived longer and had longer drug exposure and greater likelihood of developing HTN. Similarly, results of landmark analyses, with significance for both TTP and PFS at 6 weeks and significance for TTP, PFS, and OS at 12 weeks, suggest that the correlation between HTN and improved efficacy did not arise from the selection of patients who may not have remained on the study long enough to develop HTN and was independent of the time of HTN onset. Furthermore, efficacy benefits remained significant in both univariate and multivariate analyses. While similar results have been reported for sunitinibassociated HTN in RCC [19] , our findings in GIST are notable, given the differences in mechanisms of tumor growth and sunitinib antitumor activity between GIST and RCC. The proangiogenic growth factor VEGF likely plays a more prominent role in RCC pathobiology [26] than it does in GIST, in which KIT is recognized as the primary driver of tumor growth [27] . Moreover, KIT inhibition does not appear to be associated with HTN, since HTN incidences are lower with TKIs that inhibit predominantly KIT and PDGFR, such as imatinib, nilotinib, and dasatinib [28] [29] [30] than with agents targeting the VEGF signaling pathway. Therefore, in GIST, correlation between antitumor efficacy, driven by KIT inhibition, and HTN, primarily a VEGF-mediated process, is somewhat unexpected. A possible explanation for our findings may be that VEGF pathway inhibition is a more important contributor to anti-GIST activity than previously thought. 
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In contrast to the aforementioned analysis of sunitinibinduced HTN in RCC [19] , which reported efficacy results segregated by elevated SBP or DBP, we utilized a combined definition for HTN of elevated SBP and/or DBP, an approach that is consistent with criteria for HTN used by both JNC 7 and NCI CTCAE [24, 25] and is frequently used in clinical practice. However, the alternative approach of analyzing data for HTN segregated by elevated SBP or DBP in patients with GIST produced consistent, if somewhat less robust, results, which were also supported by multivariate, time-dependent covariate, and landmark analyses (data not shown).
Despite our finding a lack of correlation between sunitinib RDI and maximum SBP and DBP, we cannot exclude the possibility that associations between clinical outcomes and HTN may result from increased drug exposure. However, in a recent meta-analysis of sunitinib pharmacokinetic and pharmacodynamic data, DBP changes and sunitinib trough plasma concentrations were weakly correlated, suggesting substantial variability in DBP elevation at particular sunitinib trough plasma concentrations [31] . Additionally, whether sunitinib trough plasma concentration is the most accurate measure of the degree of target inhibition has not been determined. Measurement of an on-target effect may more readily assess the degree of clinically relevant target inhibition. The potential for such an association was shown in a study linking reduced phosphorylation of both PDGFR-β and VEGFR-2 with improved outcomes ( partial response or prolonged stable disease) in sunitinib-treated patients with GIST [32] .
Incidences of HTN-related AEs were low and comparable in advanced GIST patients with and without HTN. Clinical outcomes were not compromised in patients who used antihypertensive medications, suggesting that sunitinibinduced HTN may be successfully controlled in many patients without reductions in sunitinib dosing or interruptions in treatment. Similar findings have been reported with inhibitors of the VEGF signaling pathway, including sunitinib, in other tumor types [33, 34] . In the present analysis, patients with HTN did have a somewhat higher incidence of cardiovascular AEs compared with patients without HTN. Cardiovascular AEs have been shown to contribute very little to overall mortality in patients treated with sunitinib [20, 35, 36] , but results from this analysis and other studies highlight the importance of regular cardiovascular monitoring with sunitinib to maximize clinical benefit. Specific recommendations for assessment, monitoring, and management of HTN associated with therapies targeting the VEGF signaling pathway have been published recently [37] .
Due to limitations inherent in this retrospective design, our results do not definitely establish HTN as a biomarker of sunitinib efficacy in GIST. Specific limitations include a lack of complete pharmacokinetic data, variability in BP characteristics across studies, and lack of agreement concerning the most reliable BP parameters in this setting. Our use of threshold levels of SBP and/or DBP to define HTN may not have constituted the most precise approach to characterizing sunitinib-induced HTN. Other studies investigating the phenomenon of VEGF inhibitor-induced HTN have used both threshold levels and DBP increases from baseline to define HTN [12, 38] . However, these studies did not report whether clinical outcomes were more strongly associated with one definition or the other. Future prospective studies should be conducted to determine which definition most closely correlates with clinical outcomes. Finally, the results obtained with TTP and PFS in the time-dependent covariate analysis in the present study raise the possibility that the apparent association observed between HTN and improved disease control is related to longer times on treatment.
Establishing surrogate end points for treatment outcomes with targeted therapies in GIST are an important priority. Correlations between clinical outcomes with sunitinib in GIST and decreases in plasma levels of sKIT have been demonstrated [39, 40] . Preliminary reports of associations between other sunitinib AEs, such as neutropenia and hand-foot syndrome, and improved efficacy outcomes in GIST and RCC have also been presented [41] [42] [43] . If prospectively validated, sunitinibassociated HTN may represent one of a few selected AEs with (7) 20 (5) 39 (4) 17 (2) 72 (5) 39 (2) Acute coronary syndrome 
